“Muscle relaxants” are frequently tested, yet the term itself is a clinical misnomer. Most of these medications do not act directly on the muscle fibers; instead, they exert their effects on the central nervous system (CNS). For the clinician, the most critical distinction to make is between Antispasticity agents (used for Upper Motor Neuron syndromes) and Antispasmodics (used for acute musculoskeletal conditions). Misusing these terms or medications can lead to significant side effects, ranging from profound sedation to life-threatening withdrawal.

---

1. The Critical Distinction: Spasticity vs. Spasm

Before selecting a medication, the physician must determine the underlying pathology:

• Spasticity: A velocity-dependent increase in muscle tone caused by an Upper Motor Neuron (UMN) lesion (e.g., Stroke, Spinal Cord Injury, Multiple Sclerosis, or CP). It is characterized by the “clasp-knife” phenomenon and hyperreflexia.
• Musculoskeletal Spasm: An involuntary, localized muscle contraction often associated with acute trauma or “trigger points” (e.g., acute low back strain). This is a peripheral or segmental issue, not a brain/cord injury.

---

2. Antispasticity Agents: Targeting the UMN

These medications are the bread and butter of Pain and are designed for long-term management of neurological tone.

I. Baclofen

Baclofen is the quintessential antispasticity medication.

• Mechanism of Action: It is a potent GABA-B receptor agonist. It works at the level of the spinal cord to inhibit the release of excitatory neurotransmitters (glutamate and aspartate) and suppresses the mono- and polysynaptic reflexes.
• Pharmacokinetics: It has a short half-life, requiring TID or QID dosing.
• Intrathecal Baclofen (ITB): For severe spasticity, a pump is used to deliver the drug directly into the CSF. This allows for high spinal concentrations with minimal systemic side effects.
• High-Yield Warning: Baclofen Withdrawal. Sudden cessation of Baclofen (especially ITB) can lead to a life-threatening withdrawal syndrome characterized by high fever, altered mental status, rebound spasticity, rhabdomyolysis, and multi-organ failure. It can mimic Malignant Hyperthermia or Neuroleptic Malignant Syndrome.

II. Tizanidine (Zanaflex)

• Mechanism of Action: A central Alpha-2 Adrenergic Agonist (similar to Clonidine). It increases presynaptic inhibition of motor neurons.
• Clinical Advantage: It is less likely to cause the global muscle weakness associated with Baclofen, making it a better choice for patients who rely on some “functional spasticity” to stand or transfer.
• Side Effects: Significant hypotension, bradycardia, and dry mouth (xerostomia). It also requires monitoring of liver function tests (LFTs).

III. Dantrolene (Dantrium)

• Mechanism of Action: The only “true” muscle relaxant. It works peripherally by blocking the Ryanodine Receptor (RyR1) on the sarcoplasmic reticulum, preventing the release of calcium needed for muscle contraction.
• Indications: Chronic spasticity and the emergency treatment of Malignant Hyperthermia.
• Black Box Warning: Hepatotoxicity. It can cause fatal hepatitis; LFTs must be monitored closely.

---

3. Antispasmodics: Targeting Acute MSK Pain

These drugs are generally used for “short-term” relief (2–3 weeks) of acute muscle strains. They are heavily associated with sedation and have a high potential for misuse.

I. Cyclobenzaprine (Flexeril)

• Mechanism of Action: Structurally related to Tricyclic Antidepressants (TCAs). It works primarily at the brainstem to reduce tonic somatic motor activity.
• Board Pearl: Because of its TCA-like structure, it has significant anticholinergic side effects (dry mouth, urinary retention, sedation) and carries a risk of Serotonin Syndrome when combined with SSRIs or SNRIs. It should be avoided in the elderly.

II. Carisoprodol (Soma)

• Mechanism of Action: Metabolized into Meprobamate, a Schedule IV barbiturate-like sedative.
• The “Holy Trinity”: This is a high-yield board and clinical concept. The combination of Carisoprodol + Opioids + Benzodiazepines is extremely dangerous and highly sought after by those with substance use disorders due to the profound respiratory depression and euphoria it produces.
• Scheduling: It is a Schedule IV controlled substance.

III. Metaxalone (Skelaxin) and Methocarbamol (Robaxin)

• Mechanism: Unknown, but believed to be general CNS depression.
• Clinical Pearl: Metaxalone has a lower sedative profile compared to cyclobenzaprine, which may make it more appropriate for daytime use in working adults.

---

4. Special Case: Benzodiazepines (Diazepam)

While Diazepam (Valium) has both antispasticity and antispasmodic properties (via GABA-A receptors), it is generally discouraged for chronic use in pain medicine due to the risk of physical dependence, cognitive impairment, and its contribution to the opioid overdose epidemic.

---

5. Summary Table for Board Review

Medication	Target	Primary Mechanism	High-Yield Fact
Baclofen	Spasticity	GABA-B Agonist	Withdrawal can be fatal.
Tizanidine	Spasticity	Alpha-2 Agonist	Causes hypotension and dry mouth.
Dantrolene	Spasticity	RyR1 Blocker (Peripheral)	Treatment for Malignant Hyperthermia.
Cyclobenzaprine	Spasm	Brainstem / TCA-like	Avoid in elderly; Serotonin Syndrome risk.
Carisoprodol	Spasm	Meprobamate metabolite	High abuse potential; Part of “Holy Trinity.”

---

6. Clinical Integration: The PM&R Approach

The goal of treating spasticity is Functional Improvement.

• If a patient uses their leg spasticity to help them pivot-transfer from a wheelchair to a bed, “over-treating” that spasticity with high-dose Baclofen will make them “floppy” and unable to transfer.
• The Stretching Foundation: No medication replaces a consistent daily stretching and range-of-motion (ROM) program. Medications are used to “lower the floor” so that physical therapy can be more effective.

---

7. High-Yield Board “Fast Facts”

• GABA-B: Baclofen’s receptor.
• GABA-A: Benzodiazepines’ receptor.
• Alpha-2: Tizanidine’s receptor (think: Clonidine).
• Ryanodine Receptor: Dantrolene’s target.
• Hepatotoxicity: Check LFTs for Tizanidine and Dantrolene.
• The Elderly: Generally avoid Cyclobenzaprine and Benzos due to fall risk and delirium (Beers Criteria).
• Malignant Hyperthermia: A hypermetabolic state triggered by volatile anesthetics or succinylcholine; treat with Dantrolene.

---

8. Historical Context: The Discovery of Baclofen

Baclofen was originally synthesized in 1962 by chemist Heinrich Keberle as a potential treatment for epilepsy. While it failed as an anticonvulsant, its profound effect on muscle tone was quickly realized. The development of the Intrathecal Baclofen Pump in the 1980s by Richard Penn revolutionized care for patients with severe spinal cord injuries, allowing for the delivery of the drug at 1/100th of the oral dose while achieving superior results. This transition from “systemic” to “targeted” delivery is a recurring theme in modern pain and PM&R medicine.